Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.31% | 2.83% | -3.48% | 12.99% | 185.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.31% | 2.83% | -3.48% | 12.99% | 185.66% |
| Cost of Revenue | 54.20% | 60.02% | 33.48% | 23.34% | -11.23% |
| Gross Profit | 3.95% | -29.85% | -26.99% | 3.50% | 1,767.75% |
| SG&A Expenses | 1.66% | -6.00% | -3.29% | 6.13% | 14.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.37% | 19.42% | 11.26% | 13.28% | 2.21% |
| Operating Income | 10.79% | -278.55% | -816.39% | -15.20% | 134.97% |
| Income Before Tax | 59.72% | -21.97% | -5.61% | -77.12% | 75.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.17% | -21.97% | -5.61% | -77.12% | 75.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.17% | -21.97% | -5.61% | -77.12% | 75.27% |
| EBIT | 10.79% | -278.55% | -816.39% | -15.20% | 134.97% |
| EBITDA | 10.78% | -277.06% | -803.16% | -15.37% | 135.07% |
| EPS Basic | 27.37% | 13.62% | 36.57% | 17.77% | 89.21% |
| Normalized Basic EPS | -353.08% | -55.84% | 5.93% | 47.78% | 102.95% |
| EPS Diluted | 15.66% | 16.37% | 37.97% | 19.46% | 88.06% |
| Normalized Diluted EPS | -958.11% | -39.84% | 12.06% | 49.79% | 101.12% |
| Average Basic Shares Outstanding | 11.03% | 18.72% | 34.66% | 54.23% | 81.71% |
| Average Diluted Shares Outstanding | 14.31% | 15.20% | 30.11% | 48.22% | 86.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |